Clinical trials: Drug Resistance, Bacterial
Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection
Aztreonam-Avibactam in Immunocompromised Hosts
The goal of this observational study is to learn about the effectiveness and safety of aztreonam-avibactam, an antibiotic used to treat infections caused by highly resistant bacteria, in adults with weakened immune systems.
- Conditions
- Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Immunocompromised Host, Drug Resistance, Multiple, Bacterial
- Trial name
- IMMUNO-AVI (NCT07890480)
- Testing
- Aztreonam-Avibactam, Ceftazidime-Avibactam Plus Aztreonam
- Where
- Argentina
- Volunteers
- 814 people
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Drug Resistance, Bacterial, Carbapenems
Wastewater Surveillance for Carbapenem-Resistant Organism Outbreak Prediction in a Chinese Tertiary Hospital
Carbapenem-resistant organisms (CRO) pose a critical threat to global public health, and hospitals serve as major epicenters for their emergence and spread.
- Conditions
- Drug Resistance, Bacterial, Carbapenems, Wastewater
- Trial name
- WW-CRO-PREDICT (NCT07804433)
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Peking Union Medical College Hospital
Drug Resistance, Bacterial
Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand
The main goal of this retrospective observational study is to understand how stepping down antibiotic treatment (called antibiotic de-escalation) affects patients who receive it compared to those who don't after received a…
- Conditions
- Drug Resistance, Bacterial, Bacteremia
- Trial name
- NCT07082465
- Where
- 4 sites in Thailand
- Volunteers
- 108,000 people
- Sponsor
- University of Oxford
Hematologic Neoplasms, Gram-Negative Bacterial Infections
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
This is a prospective, single-arm, observational, exploratory clinical study to evaluate whether the standard fixed dose of ceftazidime-avibactam (CAZ-AVI) achieves sufficient drug exposure (pharmacokinetic/pharmacodynamic, or…
- Conditions
- Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections
- Trial name
- CZA-TDM (NCT07703644)
- Testing
- Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sizhou Feng
Pseudomonas Infections, Pseudomonas Aeruginosa
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as…
- Conditions
- Pseudomonas Infections, Pseudomonas Aeruginosa, Prognosis, Drug Resistance, Multiple, Bacterial
- Trial name
- ADDICT (NCT06738771)
- Where
- 48 sites in France, Reunion
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Clostridioides Difficile Infection, Drug Resistance, Bacterial
Effect of Oral Microbiota on MDRO Decolonization
Randomized, placebo-controlled trial to evaluate the safety and efficacy of oral intestinal microbiota capsules for decolonizing multidrug-resistant organisms (MDROs) and Clostridioides difficile in patients requiring prolonged…
- Conditions
- Clostridioides Difficile Infection, Drug Resistance, Bacterial, Gastrointestinal Microbiome, Multidrug-resistant Colonization
- Trial name
- NCT07496502
- Testing
- Microbiota capsule
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection
Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation
This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a…
- Conditions
- Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance
- Trial name
- NCT07226557
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Antimicrobial Stewardship, Drug Resistance, Bacterial
Optimising Community Antibiotic Use and Infection Control With Behavioural Interventions in Burkina Faso and DR Congo
Emergence of antibiotic resistance (AMR) is a serious concern for Low and Middle Income Countries (LMICs). Unregulated use of antibiotics, a major AMR driver, is highly prevalent in LMICs, with medicine stores as key providers.
- Trial name
- CABU-B/C (NCT05378880)
- Testing
- Behavioural intervention bundle to optimise antibiotic use and reduce the risk of human-to-human or environmental-animal-human transmission
- Where
- 2 sites in Burkina Faso, Democratic Republic of the Congo
- Volunteers
- 5,532 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
ACS - Acute Coronary Syndrome, Ticagrelor
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to…
- Conditions
- ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota, Platelet Aggregation
- Trial name
- FLORA-ACS (NCT07203846)
- Testing
- Rifaximin
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Premature Rupture of Membranes, Enterobacteriaceae
Prevalence of Carriage of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteria in Preterm Premature Rupture of Membranes : A French Multicenter Cohort Study
This study looks at how common certain antibiotic-resistant bacteria (called extended-spectrum beta-lactamase-producing Enterobacteriaceae, or E-BLSE) are in pregnant women who experience premature breaking of their water before…
- Conditions
- Premature Rupture of Membranes, Enterobacteriaceae, Beta-Lactams, Drug Resistance, Bacterial
- Trial name
- NCT07200999
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Resistance Bacterial, Increased Drug Resistance
Decreasing Irrational Antimicrobial Use in Bangladesh: A Digital Intervention Program
We developed 'SmartAMR', a digital pharmacy system featuring real-time records, symptom checks, telemedicine, counselling, and medication reminders.
- Conditions
- Resistance Bacterial, Increased Drug Resistance, Drug Resistance, Microbial
- Trial name
- SmartAMR (NCT06313619)
- Testing
- SmartAMR
- Where
- Bangladesh
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Drug Resistance, Bacterial, Antimicrobial Drug Resistance
Comparison of Three Interventions for Antibiotic-Resistant Bacteria (ARB) Decolonization From the Gastrointestinal Tract
The aim of this research experiment is to evaluate the effectiveness of fecal microbiota transplantation (FMT) preceded by antibiotic pre-treatment versus probiotic therapy and a standard-of-care equivalent diet designed to…
- Trial name
- STOP-ARB3 (NCT07094984)
- Testing
- Fecal microbiota transplantation (FMT), Probiotic Therapy, Gut Microbiota Boosting Diet
- Where
- Poland
- Volunteers
- 360 people
- Sponsor
- Medical University of Warsaw
Drug Resistance, Multiple, Bacterial, Cholangiopancreatography, Endoscopic Retrograde
Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries
The duodenoscopes currently used for Endoscopic Retrograde Cholangio - and Pancreaticography (ERCP) examinations are reusable and are therefore washed and disinfected after each use.
- Trial name
- PREVENT (NCT05303662)
- Testing
- Multidrug-Resistant Organisms (MDRO) testing through rectal and oral/nasal swabs, MDRO-testing duodenal aspirate, Microbiome through rectal swab
- Where
- 4 sites in United States, India and 2 more
- Volunteers
- 1,244 people
- Sponsor
- Marco J. Bruno
Pneumonia, Ventilator-Associated, Stenotrophomonas Maltophilia
Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients
This study looks at how different antibiotic treatments affect patients in intensive care who have pneumonia caused by the bacteria Stenotrophomonas maltophilia.
- Conditions
- Pneumonia, Ventilator-Associated, Stenotrophomonas Maltophilia, Intensive Care Units, Anti-Bacterial Agents
- Trial name
- NCT07052604
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Staphylococcus Haemolyticus, Staphylococcal Infections
Staphylococcus Haemolyticus in the Neonatal Intensive Care Unit of CHSD in 2023: Analysis and Trends
This study looks at cases of Staphylococcus haemolyticus infections in newborns hospitalized in the Neonatal Intensive Care Unit (NICU) at the Saint-Denis Hospital in 2023.
- Conditions
- Staphylococcus Haemolyticus, Staphylococcal Infections, Sepsis, Catheter-Related Infections
- Trial name
- NCT07013864
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Drug Resistance, Multiple, Bacterial Infections
Prediction of Multidrug-resistant Bacterial Infection in Patients with Cirrhosis
The aim of this study is to identify predictive factors of infections caused by multidrug-resistant organisms in patients with cirrhosis and to develop and validate (internally and externally) a predictive model that might be…
- Conditions
- Drug Resistance, Multiple, Bacterial Infections, Liver Cirrhosis
- Trial name
- NCT05641025
- Where
- Argentina
- Volunteers
- 1,774 people
- Sponsor
- Hospital Italiano de Buenos Aires
Urinary Tract Infections, Enterobacteriaceae Infections
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
This study evaluates the efficacy in achieving clinical cure in non-bacteremic urinary tract infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae producers of extended-spectrum β-lactamases (ESBL) in adult…
- Conditions
- Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria, Carbapenem
- Trial name
- CAPITIS (NCT03891433)
- Testing
- Meropenem, Ertapenem 1000 MG, Piperacillin, Tazobactam 4-0.5G Solution for Injection
- Where
- Colombia
- Volunteers
- 198 people
- Sponsor
- Universidad del Norte
Antimicrobial Drug Resistance, Antibiotic Resistant Infection
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or…
- Conditions
- Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection
- Trial name
- DYNAMITE (NCT06258551)
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Drug Resistance, Bacterial, Antimicrobial Drug Resistance
Fecal Microbiota Transplantation (FMT) to Decolonize Antibiotic - Resistant Bacteria (ARB) - New Protocol
The aim of the study is to assess the safety and efficacy of new protocol fecal microbiota transplantation (FMT) in the eradication of antibiotic resistant bacteria, including those featuring of resistance to new generation…
- Trial name
- STOP-ARB2 (NCT06156956)
- Testing
- Fecal Microbiota Transplantation
- Where
- 5 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Human Biome S.A.
Bacterial Infection, Multiple-drug Resistance
Intravenous Fosfomycin Pharmacokinetics Study
This is a Phase 1, open-label, multiple-dose trial conducted at a single center. The treatment period will consist of three 6 g doses (18 g) of ZTI-01 as a 1-hour intravenous (IV) infusion (+10 minute window).
- Conditions
- Bacterial Infection, Multiple-drug Resistance, Pathogen Resistance
- Trial name
- NCT03910673
- Testing
- Fosfomycin disodium
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)